IVS-3001 is under clinical development by Invectys and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Metastatic Renal Cell Carcinoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IVS-3001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IVS-3001 overview

Gene therapy is under development for the treatment of cancer especially solid tumors including advanced or metastatic clear cell renal cell carcinoma (RCC), epithelial ovarian cancer. The therapy comprises CAR-T cells targeting human leukocyte antigen-G (HLA-G). The drug candidate is developed on HLA-G platform. It is administered through intravenous route.

Invectys overview

Invectys is a biopharmaceutical company that develops immunotherapy to treat cancer. The company product pipeline includes INVAC-1, a DNA vaccine targeting Telomerase; Universal Cancer Peptide vaccine UCPVax. It offers products such as a human telomerase peptide-based vaccine; INMAB-1, a monoclonal antibody; and TelVet, a dog telomerase DNA-based anti-cancer vaccine similar to INVAC-1. Invectys TelVet is developed for the treatment of pet cancers such as dog cancers. The company’s technology restores and mobilizes the anti-tumor ability of the immune system of cancer patients. Invectys is headquartered in Paris, Ile-de-France, France

For a complete picture of IVS-3001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.